ASCO updates NSCLC pathways (driver+ and driver–)

Living guideline revision widens targeted options (HER2/MET/RET/NTRK) and refines IO strategies by PD-L1 status and stage.

KEYNOTE-585: pembro+chemo misses OS in advanced gastric cancer

Final analysis shows no OS advantage over chemotherapy alone despite earlier promise.

Breastfeeding after breast cancer in BRCA carriers appears safe

Emerging evidence supports breastfeeding in survivorship planning for BRCA-mutated patients.

Zongertinib gets FDA AA for HER2+ NSCLC

New HER2-targeted option based on early response data in a defined NSCLC subset.

Dordaviprone (Modeyso) wins FDA AA for diffuse midline glioma

Addresses H3 K27M-mutated disease in pediatric and young adult populations.

Nirogacestat approved in EU for desmoid tumors

Gamma-secretase inhibitor expands access for patients with desmoid tumors across Europe.

MMR IHC pharmDx approved as CRC IO companion diagnostic

Enables nivolumab/ipilimumab selection in MSI-H/dMMR colorectal cancer.

Haystack MRD test gains FDA Breakthrough Device designation

Stage II CRC assay may refine adjuvant decisions by detecting minimal residual disease.

Early device study shows high bladder tumor clearance

Minimally invasive approach eliminated tumors in 4 of 5 cases in preliminary data.

ArteraAI Prostate: first FDA-cleared AI prognostic in oncology

Regulatory milestone for AI-based long-term outcome prediction in prostate cancer.

Mount Sinai debuts AI to enhance tissue analysis

Institutional platform aims to speed and standardize histopathology interpretation.

What changed and why it matters for clinic tomorrow

Driver-positive disease: Clearer first-line sequences and expanded targeted options for HER2, MET, RET, and NTRK alterations; reinforce rapid reflex testing to avoid chemo/IO missteps.

Driver-negative disease: Immunotherapy pathways refined by PD-L1 strata; guidance on combinations vs monotherapy and sequencing at progression.

Stage III/IV: Consolidation IO after CRT clarified with timing/selection points; emphasis on sustained surveillance and toxicity management.

Diagnostics: Upfront comprehensive molecular profiling and PD-L1 testing emphasized to anchor first-line decision-making.